Paul Miranda, MD

Board-Certified in Family Medicine · Emergency Physician · Obesity Medicine Association member

I’m an emergency and Family Medicine physician in Chattanooga, Tennessee, and founder of Summit Metabolic Health. I read every patient chart personally. This article reports on a topic patients keep asking about — it is education, not an endorsement.

Medically reviewed by Paul Miranda, MD

I’m Dr. Paul Miranda. I work ER shifts here in Chattanooga, and I run Summit Metabolic Health, a physician-led telehealth practice based in this city. Patients ask me “how long can I stay on semaglutide” like there’s a ceiling somewhere — a number of months after which the drug becomes unsafe or unnecessary. There isn’t one. Here’s the honest part: that’s the wrong question. Semaglutide is chronic-disease management for a chronic disease. Nobody asks their cardiologist how long they can stay on a blood pressure medication that’s working.

Obesity behaves like other chronic conditions your body regulates aggressively: blood pressure, blood sugar, cholesterol. You don’t “graduate” from a statin because your LDL came down. You stay on it because the drug is doing the work, and stopping lets the underlying biology reassert itself. Semaglutide works the same way. It isn’t a 12-week reset or a detox. It’s a GLP-1 receptor agonist that suppresses appetite and slows gastric emptying for as long as it’s in your system, and your body’s hunger signaling returns once it isn’t.

The 12-week-program framing comes from how a lot of telehealth platforms package the drug, not from the pharmacology or the trial data. Nothing in the evidence tells you to stop at three months, six months, or a year. The evidence argues the opposite.

The two largest semaglutide trials never found a point where staying on it stopped helping.

STEP 1 (Wilding et al., NEJM, 2021) followed patients for 68 weeks. Weight loss was still climbing when the trial ended — no plateau, no point where the curve flattened out and said “this is as good as it gets.” The trial stopped measuring before the drug stopped working.

SELECT (Lincoff et al., NEJM, 2023) followed overweight and obese patients without diabetes for roughly three to four years, the longest-duration outcomes data we have for a GLP-1. It found a sustained 20% reduction in major adverse cardiovascular events — heart attack, stroke, cardiovascular death — in patients who stayed on semaglutide. Read that carefully: these are trial averages, not a promise about any one patient. But the pattern across both trials points the same direction. The benefit holds up over years, and it appears to depend on staying on the medication, not on finishing a course of it.

Neither trial was designed to answer “how long is too long.” Nobody has found that ceiling yet. Compare that to how most DTC marketing frames duration — a 3-month “transformation,” a 6-month “program” — and the mismatch is obvious. The trials that actually ran the longest found more benefit the longer patients stayed on, not less.

Semaglutide has a half-life of about seven days, which means it takes roughly five weeks after your last dose to clear your system fully. As it clears, appetite suppression fades first, usually within a few weeks. Hunger signals you hadn’t felt in months come back. That’s not a personal failure. It’s the drug leaving and the underlying biology picking back up where it left off — the same mechanism I’ve laid out in detail for why most people gain weight back after stopping a GLP-1.

This matters because the question patients actually mean when they ask “how long can I stay on it” is usually “when do I get to stop.” For most patients who haven’t reached a stable goal weight and plateaued there under physician monitoring, stopping early just restarts the clock. The weight that comes back isn’t a reflection of willpower. It’s pharmacology doing exactly what it does when the drug is gone.

I see this pattern most often in patients who stopped for a reason that had nothing to do with their chart — a lapsed prescription, a price increase, a plan that ran out of refills without warning. None of those are medical reasons to stop. They’re administrative ones, and the regain that follows is just as real either way.

Every comparison article that answers “how long can you stay on semaglutide” stops at drug safety and skips the part that actually determines whether patients stay on it: the price tag attached to staying.

Ro and Hims advertise an attractive introductory rate that climbs once the honeymoon period ends, landing long-term patients at $349 to $548 a month. Henry Meds runs $297 to $399 a month indefinitely, with no discount for patients who’ve stabilized. In every one of those structures, the longer you stay on therapy — the exact thing STEP 1 and SELECT say you should do — the more it costs you. That’s a step-up model, and it penalizes the patients doing the right thing.

Summit runs the opposite direction. Once a patient hits goal weight, the fee drops to $99 a month. Staying on long-term maintenance costs less, not more. I don’t have an incentive to keep you on a higher dose or a higher tier once your chart says you’re stable — a dynamic I’ve written about directly when comparing Summit to Hims on price and oversight. A platform optimizing for churn and upsell has no structural reason to build pricing that way. A practice built around one physician reading your actual chart does.

Here’s a question almost no DTC platform answers honestly: who actually decides if or when you taper, and on what basis? At a lot of national telehealth companies, the honest answer is a scaled panel of nurse practitioners and PAs working off a protocol, not a physician who knows your case. The decision gets made by algorithm or by default — the subscription just continues.

At Summit, that decision is mine. I’m a board-certified family medicine physician, and I personally review every chart — not a questionnaire routed through software, not a queue. Tapering is a decision built on your weight trajectory, your labs, your side-effect burden, and your goals, not on a contract term or a pricing tier. For some patients that means staying on a maintenance dose indefinitely. For others who’ve been stable at goal for months, it means a structured, descending-dose taper with follow-up visits to confirm the trend holds — the same clinical logic I use when a patient asks about what actually happens when you stop a GLP-1 class medication. Neither path is a default. I don’t apply a standing protocol to everyone. I look at the chart in front of me.

If you’re asking how long you can stay on semaglutide, the trial data and the pricing math point the same direction: staying on it, under a physician who’s actually watching your labs and your weight trend, is the better-supported path for most patients who are still responding. Stopping should be a clinical call made with you, not a decision forced by a bill climbing past what you signed up for.

I’m in Chattanooga. Care is telehealth, but the physician running it lives and works in your city. You can read more of the research behind GLP-1 care on the Summit Metabolic Health blog.

Ready to start? Apply at summitmetabolichealth.com/apply.

This post is educational and isn’t a substitute for individualized medical care. Talk with your prescribing physician before changing your semaglutide dose or stopping treatment.